Cargando…
The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials
Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, and degenerative disease that affects the central nervous system. A recent study showed that interaction between the immune system and the gut microbiota plays a crucial role in the development of MS. This review reports the clinical...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923550/ https://www.ncbi.nlm.nih.gov/pubmed/31512505 http://dx.doi.org/10.1177/0963689719873890 |
_version_ | 1783481555409174528 |
---|---|
author | Schepici, Giovanni Silvestro, Serena Bramanti, Placido Mazzon, Emanuela |
author_facet | Schepici, Giovanni Silvestro, Serena Bramanti, Placido Mazzon, Emanuela |
author_sort | Schepici, Giovanni |
collection | PubMed |
description | Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, and degenerative disease that affects the central nervous system. A recent study showed that interaction between the immune system and the gut microbiota plays a crucial role in the development of MS. This review reports the clinical studies carried out in recent years that aimed to evaluate the composition of the microbiota in patients with relapsing–remitting MS (RR-MS). We also report what is available in the literature regarding the effectiveness of fecal microbiota transplantation and the role of the diet in restoring the intestinal bacterial population. Studies report that patients with RR-MS have a microbiota that, compared with healthy controls, has higher amounts of Pedobacteria, Flavobacterium, Pseudomonas, Mycoplana, Acinetobacter, Eggerthella, Dorea, Blautia, Streptococcus and Akkermansia. In contrast, MS patients have a microbiota with impoverished microbial populations of Prevotella, Bacteroides, Parabacteroides, Haemophilus, Sutterella, Adlercreutzia, Coprobacillus, Lactobacillus, Clostridium, Anaerostipes and Faecalibacterium. In conclusion, the restoration of the microbial population in patients with RR-MS appears to reduce inflammatory events and the reactivation of the immune system. |
format | Online Article Text |
id | pubmed-6923550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-69235502020-01-03 The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials Schepici, Giovanni Silvestro, Serena Bramanti, Placido Mazzon, Emanuela Cell Transplant Reviews Multiple sclerosis (MS) is a chronic, inflammatory, demyelinating, and degenerative disease that affects the central nervous system. A recent study showed that interaction between the immune system and the gut microbiota plays a crucial role in the development of MS. This review reports the clinical studies carried out in recent years that aimed to evaluate the composition of the microbiota in patients with relapsing–remitting MS (RR-MS). We also report what is available in the literature regarding the effectiveness of fecal microbiota transplantation and the role of the diet in restoring the intestinal bacterial population. Studies report that patients with RR-MS have a microbiota that, compared with healthy controls, has higher amounts of Pedobacteria, Flavobacterium, Pseudomonas, Mycoplana, Acinetobacter, Eggerthella, Dorea, Blautia, Streptococcus and Akkermansia. In contrast, MS patients have a microbiota with impoverished microbial populations of Prevotella, Bacteroides, Parabacteroides, Haemophilus, Sutterella, Adlercreutzia, Coprobacillus, Lactobacillus, Clostridium, Anaerostipes and Faecalibacterium. In conclusion, the restoration of the microbial population in patients with RR-MS appears to reduce inflammatory events and the reactivation of the immune system. SAGE Publications 2019-09-12 2019-12 /pmc/articles/PMC6923550/ /pubmed/31512505 http://dx.doi.org/10.1177/0963689719873890 Text en © The Author(s) 2019 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Reviews Schepici, Giovanni Silvestro, Serena Bramanti, Placido Mazzon, Emanuela The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical Trials |
title | The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical
Trials |
title_full | The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical
Trials |
title_fullStr | The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical
Trials |
title_full_unstemmed | The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical
Trials |
title_short | The Gut Microbiota in Multiple Sclerosis: An Overview of Clinical
Trials |
title_sort | gut microbiota in multiple sclerosis: an overview of clinical
trials |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923550/ https://www.ncbi.nlm.nih.gov/pubmed/31512505 http://dx.doi.org/10.1177/0963689719873890 |
work_keys_str_mv | AT schepicigiovanni thegutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials AT silvestroserena thegutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials AT bramantiplacido thegutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials AT mazzonemanuela thegutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials AT schepicigiovanni gutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials AT silvestroserena gutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials AT bramantiplacido gutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials AT mazzonemanuela gutmicrobiotainmultiplesclerosisanoverviewofclinicaltrials |